Spero Therapeutics (NASDAQ:SPRO) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a hold rating to a buy rating in a report released on Thursday morning, ValuEngine reports.

A number of other analysts have also commented on SPRO. Zacks Investment Research lowered Spero Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 17th. TheStreet lowered Spero Therapeutics from a c- rating to a d+ rating in a research note on Monday, July 29th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $19.50.

Shares of SPRO traded down $0.48 during trading hours on Thursday, reaching $9.09. 1,376 shares of the company traded hands, compared to its average volume of 44,250. The company has a debt-to-equity ratio of 0.04, a current ratio of 17.48 and a quick ratio of 17.48. The company has a market cap of $161.89 million, a PE ratio of -3.55 and a beta of 2.08. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $14.48. The company’s fifty day moving average price is $11.28.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.49. The business had revenue of $7.72 million for the quarter, compared to analyst estimates of $1.25 million. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. On average, equities analysts forecast that Spero Therapeutics will post -3.06 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Spero Therapeutics by 5.7% during the fourth quarter. BlackRock Inc. now owns 393,630 shares of the company’s stock worth $2,421,000 after buying an additional 21,161 shares during the period. Northern Trust Corp lifted its position in Spero Therapeutics by 1.1% during the fourth quarter. Northern Trust Corp now owns 96,833 shares of the company’s stock worth $595,000 after buying an additional 1,038 shares during the period. Geode Capital Management LLC lifted its position in Spero Therapeutics by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 91,842 shares of the company’s stock worth $564,000 after buying an additional 3,876 shares during the period. Bank of America Corp DE lifted its position in Spero Therapeutics by 2,036.1% during the fourth quarter. Bank of America Corp DE now owns 83,009 shares of the company’s stock worth $510,000 after buying an additional 79,123 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Spero Therapeutics by 31.9% during the fourth quarter. Bank of New York Mellon Corp now owns 36,716 shares of the company’s stock worth $226,000 after buying an additional 8,888 shares during the period. Hedge funds and other institutional investors own 46.70% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Recommended Story: What is a Backdoor Roth IRA?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.